Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray

被引:31
作者
Harris, Loleta D. [1 ]
De La Cerda, Jorge [1 ]
Tuziak, Tomasz [4 ]
Rosen, Daniel [4 ]
Xiao, Lianchun [2 ]
Shen, Yu [2 ]
Sabichi, Anita L. [3 ]
Czerniak, Bogdan [4 ]
Grossman, H. Barton [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
关键词
bladder neoplasms; tumor markers; tissue microarray analysis;
D O I
10.1002/mc.20420
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dysregulation of Akt, PTEN, Drg-1, Cx-26, and L-plastin expression appear to be important in the progression of various cancers. Their expression in bladder cancer has not been well characterized. To assess the expression of these genes and their relationship to the outcome of bladder cancer, we used a bladder cancer tissue microarray (TMA) of 251 transitional cell carcinomas. We quantitated immunohistochemical staining of each protein using both automated and manual methods and correlated the expression levels with the clinicopathologic characteristics of the tumor and patient survival. Overall, the results from both automated and manual analyses were similar. We found a significant correlation between the expression of PTEN, Cx-26 and L-plastin with known clinically important pathologic features of bladder cancer (tumor grade, stage, and growth pattern). Aberrant localization patterns of Cx-26 and Drg-1 were observed in bladder tumors. There was also a significant correlation in expression among pAkt, PTEN, and L-plastin. Although the expression of these genes correlated with factors known to be associated with patient outcome, none of them was an independent predictor of progression-free or overall survival. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:678 / 685
页数:8
相关论文
共 32 条
[1]   PTEN up-regulates the tumor metastasis suppressor gene Drg-1 in prostate and breast cancer [J].
Bandyopadhyay, S ;
Pai, SK ;
Hirota, S ;
Hosobe, S ;
Tsukada, T ;
Miura, K ;
Takano, Y ;
Saito, K ;
Commes, T ;
Piquemal, D ;
Watabe, M ;
Gross, S ;
Wang, Y ;
Huggenvik, J ;
Watabe, K .
CANCER RESEARCH, 2004, 64 (21) :7655-7660
[2]   The Akt pathway in human breast cancer: a tissue-array-based analysis [J].
Bose, S ;
Chandran, S ;
Mirocha, JM ;
Bose, N .
MODERN PATHOLOGY, 2006, 19 (02) :238-245
[3]   Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis [J].
Chung, JH ;
Eng, C .
CANCER RESEARCH, 2005, 65 (18) :8096-8100
[4]   Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer [J].
Dominguez-Escrig, JL ;
Kelly, JD ;
Neal, DE ;
King, SM ;
Davies, BR .
CLINICAL CANCER RESEARCH, 2004, 10 (14) :4874-4884
[5]   Connexin 26 is abnormally expressed in bladder cancer [J].
Gee, J ;
Tanaka, M ;
Grossman, HB .
JOURNAL OF UROLOGY, 2003, 169 (03) :1135-1137
[6]   Increased expression of connexin 26 in the invasive component of lung squamous cell carcinoma: Significant correlation with poor prognosis [J].
Ito, A ;
Koma, Y ;
Uchino, K ;
Okada, T ;
Ohbayashi, C ;
Tsubota, N ;
Okada, M .
CANCER LETTERS, 2006, 234 (02) :239-248
[7]  
Ito A, 2002, HISTOL HISTOPATHOL, V17, P951, DOI 10.14670/HH-17.951
[8]   Alterations in connexin26 expression during colorectal carcinogenesis [J].
Kanczuga-Koda, L ;
Sulkowski, S ;
Koda, M ;
Sulkowska, M .
ONCOLOGY, 2005, 68 (2-3) :217-222
[9]   Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways [J].
Kim, JH ;
Tuziak, T ;
Hu, LM ;
Wang, Z ;
Bondaruk, J ;
Kim, MS ;
Fuller, G ;
Dinney, C ;
Grossman, HB ;
Baggerly, K ;
Zhang, W ;
Czerniak, B .
LABORATORY INVESTIGATION, 2005, 85 (04) :532-549
[10]   Differential PTEN protein expression profiles in superficial versus invasive bladder cancers [J].
Koksal, IT ;
Yasar, D ;
Dirice, E ;
Usta, MF ;
Karauzum, S ;
Luleci, G ;
Baykara, M ;
Sanlioglu, S .
UROLOGIA INTERNATIONALIS, 2005, 75 (02) :102-106